← boardnext 2026-09-30next 2026-11-30next 2029-03
QURE
UniQure Biopharma B.V.distress 5/10 · elevated risk$39.76-2%today-44% from 52w high
Lead: refractory mesial temporal lobe epilepsy
Revenue
pre-revenue
Liquidity
$140M
Runway
0.8 yrs
Shares 1y
+15%
Price & events
+75.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
+1.0%
1W
-18.9%
1M
+126.7%
3M
+58.5%
6M
+158.5%
1Y
+394.8%
2Y
+52.9%
5Y
+8.2%
All
Overview
- Market Cap
- $2.51B
- Enterprise Value
- $2.42B
- Volume
- 37.32K
- 52 Week Range
- $9.03 – $70.59
- Total Shares
- 63.07M
- Float Shares
- 56.53M
- Short %
- 16.95%
- % Held by Insiders
- 1.29%
- % Held by Institutions
- 90.03%
- RVOL
- 0.02x
- Beta
- 0.90
Pipeline stages · 3 programs
AMT-191
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AAV9-hSyn1-miGRIK2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
intra-striatal rAAV5-miHTT
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-30 Estimated 50% readout ~2026-11-14 | Phase 1/2 | AMT-162rmatorphanfast trackbreakthrough | Amyotrophic Lateral Sclerosis | — | active not recruiting |
| 2026-11-30 Estimated 50% readout ~2027-01-14 | Phase 1/2 | AAV9-hSyn1-miGRIK2 | Mesial Temporal Lobe Epilepsy | — | recruiting |
| 2027-12-01 Estimated 50% readout ~2028-01-15 | Phase 1/2 | AMT-191rmatorphanfast trackbreakthrough | Fabry Disease | — | recruiting |
| 2029-03 Estimated 50% readout ~2029-04-15 | Phase 1/2 | intra-striatal rAAV5-miHTT | Huntington Disease | — | active not recruiting |
| 2029-06 Estimated 50% readout ~2029-07-16 | Phase 1/2 | intra-striatal rAAV5-miHTT | Huntington's Disease | — | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 15
- first half of 2027Guided 55%readoutPhase 1/2AMT-260 · Updated results from Phase I/IIa clinical trial expected.SEC 8-K
- third quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)AMT-130 · Submit MAA to UK MHRA based on three-year Phase I/II data.SEC 8-K
- over the next 3-6 monthsGuided 70%readoutPhase 1/2AMT-260 · Data readout for AMT-260 in MTLESEC 8-K
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026readoutPhase 1/2AMT-260 · Updated data from Phase I/IIa studySEC 8-K
- mid-2026enrollment completesecondaryPhase 1/2AMT-260 · Anticipated completion of enrollment in second, higher-dose cohort.SEC 8-K
- 2026-06-17fda agreementAMT-130 · FDA agreed that 3-year Phase I/II data can serve as primary basis for BLA for accelerated approvalSEC 8-K
- first quarter of 2026regulatory submissionFiled (NDA/BLA)AMT-130 · BLA submission with request for priority reviewSEC 8-K
- in 2025readoutPhase 1/2AMT-191 · initial clinical proof-of-concept dataSEC 8-K
- 2025-11-03fda agreementAMT-130 · FDA no longer agrees Phase I/II data vs external control may be adequate for BLA submission; shift from prior guidance.SEC 8-K
- third quarter of 2025readoutPhase 1/2AMT-130 · Topline Phase I/II data per SAPSEC 8-K
- 2025-06-02fda agreementAMT-130 · Alignment with FDA on statistical analysis plan and CMC for AMT-130 BLA submissionSEC 8-K
- 2024-12-10fda agreementAMT-130 · FDA agrees data from ongoing Phase I/II studies compared to natural history external control may serve as primary basis for BLA for Accelerated Approval; cUHDRS agreed as intermediate clinical endpoint.SEC 8-K
- November 21, 2024trial initiationsecondaryPhase 1/2AMT-260 · First patient dosed in GenTLE Phase I/IIa clinical trialSEC 8-K
- August 15, 2024trial initiationsecondaryPhase 1/2AMT-191 · First patient dosed in Phase I/IIa trial of AMT-191 for Fabry diseaseSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $65 (+63% upside) · 11 analysts
- 2026-06-29HC Wainwright & Co.Buy
- 2026-06-25MizuhoOutperform
- 2026-06-18BarclaysEqual-Weight → Overweight
- 2026-06-18Leerink PartnersOutperform
- 2026-06-18Goldman SachsNeutral
- 2026-06-18RBC CapitalOutperform
Competitors — refractory mesial temporal lobe epilepsy
- none identified
Recent news
- 2026-07-22uniQure sets July 29 webcast after Q2 financial results - Stock Titan
- 2026-07-22uniQure to Announce Second Quarter 2026 Financial Results - Yahoo Finance Singapore
- 2026-07-22JPMorgan Chase & Co. Increases Stake in uniQure NV - GuruFocus
- 2026-07-22Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Maintains Target Price $46 - Moomoo
- 2026-07-20Aberdeen Group plc (QURE) discloses 2.85M-share, 4.52% holding in uniQure - Stock Titan
- 2026-07-20uniQure (QURE) Proxy filing Summary - Quartr
- 2026-07-19What Caused uniQure's Dramatic Stock Plunge - Kavout | AI
- 2026-07-19uniQure (QURE) Proxy filing Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.